// App-Quantinova.ai

OT1-01-05 : AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer

Researchers

Presenter

  • Luc Dirix

Principal Investigators

  • Hans Wildiers

  • Manon T Huizing

  • Eveline De Cuypere

  • Carolina P Schrder

  • Anne C Armstrong

  • Jans Huober

  • Frederik Marm

  • Andreas Schneeweiss

  • Sarah Khan

  • Frderic Triebel

Medical Centers

  • Sint-Augustinus, Wilrijk-Antwerp, Belgium

  • Department of Surgical Oncology and Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven, Belgium

  • Breast and Gynaecological Oncology Unit, UZA, Wilrijk, Belgium

  • AZ Sint-Jan Burgge-Oostende AV, VZW Oncological Centre, Brugge, Belgium

  • University Medical Center Groningen, Nijmegen, Netherlands

  • Christie Hospital NHS Trust, Department of Medical Oncology, Manchester, United Kingdom

  • University Clinic for Women, Ulm, Germany

  • Gynaecological Oncology, Heidelberg University, University Clinic Mannheim, Mannheim, Germany

  • National Center for Tumor Diseases DKFZ, Heidelberg, Germany

  • Notthingham University Hospitals NHS Trust, Clinical Oncology, Nottingham, United Kingdom

  • Research & Development, Immutep, Paris, France

Locations

  • Belgium

  • Netherlands

  • United Kingdom

  • Germany

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

  • Hormone receptor

Drug/Treatment

  • EDP 202

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Controlled

Phase

  • II

Study Id's

  • NCT02614833

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved